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Abstract
Background Currently, there are no guidelines for neurosurgeons treating patients with Cushing’s disease (CD) when intraop-
erative adenoma identification is negative. Under these circumstances, a total hypophysectomy or hemi-hypophysectomy on the
side indicated by inferior petrosal sinus sampling (IPSS) is the approach being used, although there is a subsequent risk of
hypopituitarism. Data on whether one-third lateral pituitary gland resection results in cure of hypercortisolism and low rates of
hypopituitarism remain inconclusive.
Methods Retrospective single-center study of CD patients with failed intraoperative adenoma identification and subsequent
resection of the lateral one-third of the pituitary gland as predicted by IPSS. We assessed (i) histopathological findings, (ii) early
and long-term remission rates, and (iii) rates of additional pituitary hormone insufficiency.
Results Tenwomen and three menmet the inclusion criteria. At 3 months, remission was noted in six (46%) patients: three (23%)
had histologically confirmed adenomas, two (15%) had ACTH hyperplasia, and one patient (8%) was positive for Crooke’s
hyaline degeneration. New pituitary hormone deficits were noted in two patients (15%). After a median (±SD) follow-up of 14±4
years, recurrence was noted in two (15%) patients. Long-term control of hypercortisolismwas attained by 10 patients (77%), with
additional therapies required in nine (69%) of them.
Conclusions In CD patients with failed intraoperative adenoma visualization, lateral one-third gland resection resulted in low
morbidity and long-term remission in 31% of patients without the need for additional therapies. Bearing in mind the sample size
of this audit, the indication for lateral one-third-gland resection has to be critically appraised and discussed with the patients
before surgery.
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Cushing’s disease (CD) is the most challenging disorder
among hormone-secreting pituitary tumors [13]. CD is pre-
dominantly caused by a corticotroph pituitary microadenoma
[62]. Despite modified protocols, not infrequently magnetic
resonance imaging (MRI) fails to detect adrenocorticotropin-
secreting (ACTH) pituitary microadenomas [20, 22, 65].
Thus, bilateral inferior petrosal sinus sampling (IPSS) remains
the gold standard in identifying the source of Cushing’s syn-
drome (CS) in patients with negative or equivocal MRI find-
ings [7, 10]. Nevertheless, subsequent intraoperative explora-
tion still might reveal a pituitary gland with a normal appear-
ance [7, 10]. Under these circumstances, no commonly ac-
c ep t ed t r e a tmen t gu i d e l i n e s ex i s t , a nd hem i -
hypophysectomy―or two-thirds gland resection―has been
proposed as a valid option, with a subsequent risk of hypopi-
tuitarism [19]. Data remain inconclusive with regard to wheth-
er one-third resection of the pituitary gland on the side indi-
cated by IPSS results in high remission rates and a low rate of
additional pituitary hormone deficiencies.
In this audit of practice, we assessed (i) histopathological
findings, (ii) early and long-term remission rates, and (iii) the
rate of new pituitary hormone insufficiency in CD patients
with negative MRI findings, failed intraoperative adenoma
exploration, and subsequent lateral one-third gland resection
on the side indicated by IPSS. Emphasis was placed on
assessing the long-term outcome in these patients, given that
high long-term recurrence rates are known [11, 49].
Methods
Study design
We performed a retrospective study evaluating data from our
institutional database, which was prospectively maintained from
October 1997 to January 2016. All consecutive patients met
clinical and biochemical inclusion criteria for ACTH-dependent
CS [27, 34, 64]. Bilateral IPSS was performed due to failed
adenoma identification by pituitary MRI. Patients were included
if the adenomas could not be identified intraoperatively after
careful exploration of the entire gland at the time of
transsphenoidal surgery (TSS). Thus, the lateral one-third of the
pituitary gland was subsequently resected on the side indicated
by IPSS. Tissue was sent to pathology for histological analysis.
Early remission rates, hypopituitarism, and long-term outcome
were extracted from the medical records.
MR imaging and bilateral IPSS
PD/T2-weighted, unenhanced, contrast-enhanced, dynamic
contrast-enhanced, and post contrast-enhanced overlapping
images in three planes over the pituitary region of 1-mm
fine-cut images were collected using a 1.5 Tesla MRI [6, 9,
10]. In patients with negative MRI and ACTH-dependent CS
with equivocal responses to biochemical testing (i.e., ovine
corticotropin-releasing hormone [oCRH] stimulation and/or
high-dose dexamethasone suppression), bilateral IPSS was
indicated [7, 10]. Details of this procedure have been de-
scribed previously [7, 10]. In brief, both femoral veins were
catheterized. A Hi-Flow Tracker 18 (Renegade Hi-Flow
Microcatheter; Boston Scientific Target, Fremont, CA) was
placed into each cavernous sinus to enable classification of
the venous outflow on both sides. If the cavernous sinus could
not be catheterized, the drainage type was recorded based
upon an internal carotid artery injection. For venous blood
sampling, the microcatheter was retracted distal to the cavern-
ous sinus and placed into each proximal IPS. We determined
the venous outflow variances on each side of the IPS after
contrast injection and classified them as described by Shiu
et al. [61] and Benndorf et al. [12]. An asymmetric IPS was
defined as different venous outflow patterns of IPS seen when
comparing the left and right sides.
As proposed by Oldfield et al., mean ACTH concentration
of both the petrosal sinuses, divided by mean ACTH concen-
tration of a peripheral vein, was indicative of a central ACTH
source when gradients were ≥2.0 before and/or ≥3.0 after
oCRH stimulation [47]. As for lateralization, mean ACTH
concentration of one side of the petrosal sinuses divided by
mean ACTH concentration of the other side was positive if
gradients were ≥1.4 [46].
Microsurgery
A transnasal transsphenoidal approach under microscopic
magnification was used in all cases [28]. All operations were
performed by the senior neurosurgeon (RWS).
As microadenomas can induce limited bulging in the
surface of the gland, we created a wide opening in the
sellar floor to thoroughly expose the pituitary gland after
extensive dural opening. The superior and inferior sur-
faces of the gland, as well as the lateral walls in direct
contact with the medial wall of the cavernous sinus, were
explored, and the lateral ligaments were divided, allowing
for easier mobilization and inspection of the pituitary
gland’s lateral surface [30]. If no bulging was noticeable,
a vertical incision was made in the lateral gland on the
side where the adenoma was suspected to be found, in
order to explore the inside of the gland. Suspicious tissue
was sent for frozen sectioning. If no adenoma was con-
firmed, a lateral one-third hypophysectomy was per-
formed using pituitary rongeurs on the side indicated by
IPSS (Fig. 1). This included the bottom of the gland in
order to maximize the chance of microadenoma removal
while minimizing new endocrinopathies [24, 30, 31, 60,
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63]. Tissue was sent to pathology for histological analy-
sis. To avoid rhinoliquorrhea, the surgical defect was
filled with gelatin foam soaked in fibrin glue, and a syn-
thetic absorbable vicryl patch was used to cover the sellar
opening [3–5, 8, 10, 58].
Histopathological analyses
Histopathological analyses were performed to confirm the
presence of an ACTH-secreting adenoma. In brief, paraffin
sections were stained for hematoxylin, reticulin, and ACTH.
In addition, staining was performed for growth hormone, pro-
lactin, thyroid-stimulating hormone, luteinizing hormone, and
follicle-stimulating hormone. If no adenoma was found, the
tissue was examined for ACTH hyperplasia or positive
Crooke ’s hyal inizat ion as an indirect marker of
hypercortisolism [48].
Determination of remission rates
The early remission rate was determined 3 months postoper-
atively. Long-term remission rates were extracted ≥ 12months
postoperatively. Remission was defined as immediate postop-
erative serum cortisol <50 nmol/L and the need for a transitory
cortisol replacement therapy. In addition to improvement in
the clinical features of CS, remission was defined as normal-
ization of 24 h urinary cortisol levels, normal salivary cortisol
levels for three consecutive days, and/or a normal dexameth-
asone suppression test during the follow-up visit [27, 41, 64].
Statistical analyses
Data were analyzed using IBM SPSS statistical software
Version 24.0 (IBM Corp., New York, NY, USA) and
GraphPad Prism (V7.04 Software, San Diego, CA, USA).
Continuous variables were examined for homogeneity of var-
iance and are expressed as mean ± standard deviation (SD)
unless otherwise noted. For comparisons of means between
the two groups, Student’s t-test was used for normally
distributed data, and the Mann-Whitney test for non-
parametric data. Categorical variables were compared
using Pearson’s chi-square test or Fisher’s exact test,
as appropriate. Differences were considered significant
at p < 0.05 for reported two-sided p values.
Results
Patients’ characteristics
Ten women (77%) and three men (23%) met the study inclu-
sion criteria. Patients’ characteristics are summarized in
Table 1. Median age was 49 ± 12.4 years (range 24–63 years).
All patients had negative MRI results and underwent IPSS,
with the latter predicting a pituitary (central) lesion.
Preoperative pituitary deficits were rare. Two patients
(15%) showed isolated one-axis impairment (gonadotro-
phic deficiency in one patient and thyrotropic deficiency
in another patient).
Bilateral IPSS results
In Supplementary Table 1, classification of the venous out-
flow and documentation of the venous outflow symmetry are
summarized. In addition, central to peripheral ACTH gradi-
ents and intersinus gradients (lateralization data) before and
after oCRH stimulation are depicted.
In three patients, no data on the drainage pattern were avail-
able. Symmetric outflow was recorded in eight patients (62%)
and asymmetric outflow in two patients (15%). A central-to-
peripheral gradient ≥2.0 before oCRH stimulation was
attained in 10 patients (77%), whereas a gradient ≥3.0 after
oCRH stimulation was attained in all of them (100%). With
regard to lateralization, normalized ACTH values (i.e., side-
by-side gradients) were not significantly different between
patients with a symmetric (7.3 ± 2.6) or an asymmetric out-
flow at baseline (18.2 ± 13.4; p = 0.19), but they were signif-
icantly different after oCRH stimulation (symmetric: 9.0 ± 4.9
versus asymmetric: 141.0 ± 93.9; p = 0.01).
We further noted that ACTH gradients were higher in pa-
tients with a histologically confirmed adenoma compared to
those without, both before (19.2±8.7 vs. 6.6 ± 2.6; p=0.12)
and after (74.8± 43 vs. 9.6 ± 5.5, p=0.08) oCRH stimulation,
Fig. 1 Coronal view of the pituitary gland and parasellar region with
depiction of the surgical technique used. After an extensive opening of
the sellar floor followed by cruciate dural opening, the peripheral gland
was thoroughly explored and the lateral third (1/3) of the gland periphery
was incised on the side indicated by IPSS if no adenoma was found. The
tissue (a brownish-yellow color) of the lateral margins adjacent to the
medical wall of the cavernous sinus was resected and sent to pathology
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but not significantly. In addition, early remission rates were
found not to be significantly different in patients with higher
ACTH gradients compared to those with lower gradients, both
before (12.2 ± 5 vs. 10.8 ± 6.2, p=0.87) and after (43.1 ± 38 vs.
27.4 ± 12.6; p=0.69) oCRH stimulation.
Histopathological results
AnACTH-secreting adenoma was histologically confirmed in
five patients (39%), an ACTH hyperplasia in four (31%), pos-
itive Crooke-hyaline in three patients (23%), and a normal
pituitary gland in one patient (7%).
Rates of remission
At 3 months, remission was noted in three patients (23%) with
histologically confirmed adenomas, in two patients (15%) with
ACTH hyperplasia, and in one patient (8%) with positive
Crooke’s hyaline degeneration (Fig. 2a). When dichotomizing
patients into those with confirmed adenoma and those without,
we noted early remission in three patients (60%) with histologi-
cally confirmed adenoma vs. three (38%) without (p=0.59).
Recurrence occurred in three patients (25%) with initial
cortisol normalization. For the long-term control of
hypercortisolism, bilateral adrenalectomy was required in four
Table 1 Baseline characteristics and remission rates following lateral one-third-gland resection
Case No. Age (yrs), sex IPSS prediction Histopathology Early remission
at 3 months
Long-term remission (months) Additional therapy
1 53, m Central left Normal pituitary No Yes (203) Bilateral adrenalectomy
2 41, f Central right ACTH hyperplasia Yes Yes (156) None
3 49, f Central left Adenoma No Yes (180) Bilateral adrenalectomy
4 40, f Central right Adenoma Yes Yes (228) None
5 52, f Central left Adenoma Yes No (128) Drug-treated
6 37, f Central right ACTH hyperplasia Yes No (168) Gamma-knife surgery
7 50, f Central right Adenoma Yes Yes (171) None
8 63, f Central left ACTH hyperplasia No Yes (170) Drug-treated
9 55, m Central right ACTH hyperplasia No Yes (64) None
10 60, f Central right pos. Crooke hyaline Yes Yes (24) None
11 35, m Central left Adenoma No Yes (98) Bilateral adrenalectomy
12 25, f Central right pos. Crooke hyaline No No (72) Drug-treated
13 24, f Central right pos. Crooke hyaline No Yes (61) Bilateral adrenalectomy
No., number; yrs, years; IPSS, inferior petrosal sinus sampling; m, male; f, female; ACTH, adrenocorticotropic hormone; pos., positive.
Fig. 2 Early and long-term remission following lateral one-third-gland
resection. At early follow-up, remission was noted in six patients (46%):
three patients (23%) with histologically confirmed adenomas, two pa-
tients (15%) with ACTH hyperplasia, and one patient (8%) with positive
Crooke’s hyaline degeneration (a). Long-term remission was noted in 10
patients (77%): four patients (31%) with initially confirmed adenoma,
three patients (23%) with ACTH hyperplasia, two patients (15%) with
positive Crooke-hyaline, and one patient (8%) with negative histology (b)
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patients (33%), metyrapone therapy in three (25%), and pitu-
itary radiosurgery in one patient (8%) (Table 1).
After a median (±SD) follow-up of 14±4 years, long-term
remission was noted in 10 patients (77%): four (31%) with
initially confirmed adenoma, three (23%) with ACTH-hyper-
plasia, two (15%) with positive Crooke-hyaline, and one pa-
tient (8%) with negative histology (Fig. 2b).
Complications of therapeutic interventions
No mortality due to the surgical intervention was noted.
Postoperative complications consisted of rhinoliquorrhea in
one patient―requiring temporary lumbar cerebrospinal fluid
drain―and transient diabetes insipidus in another patient.
New postoperative deficits requiring hormonal replacement
were noted in two patients (15%), with testosterone replace-
ment in one patient and additional growth hormone replace-
ment in a patient with preoperative thyrotropic deficiency. We
noted no vascular injuries, meningitis, or abscesses [57].
Discussion
Our data show that in CD patients with failed intraoperative
adenoma visualization, (i) lateral one-third gland resection
resulted in low rates of additional pituitary insufficiencies,
but also in low cure rates of hypercortisolism, and (ii) high
long-term remission rates (>10 years) can be attained, but only
with an interdisciplinary multimodal approach.
CD is the most challenging disorder among hormone-
secreting pituitary tumors [42, 54]. This has been attrib-
uted to difficulty both in the diagnosis and treatment of
primarily microadenomas, along with the accuracy of tests
in the assessment of endogenous hypercortisolism [7].
TSS is considered the first-line treatment for CD, provid-
ing remission in 59–90% of patients in dedicated tertiary
pituitary centers [33]. Thereby, a risk factor for persistent
hypercortisolism has been attributed to unsuccessful intra-
operative adenoma identification [19, 33, 51]. For these
cases, total hypophysectomy or hemi-hypophysectomy
has been proposed―but at the expense of hypopituitarism
[55]. Our approach resulted in low morbidity and long-
term cure in 31% of patients. Likewise, early remission
has been described in 11 CD patients (38%) with negative
adenoma iden t i f i c a t i on and subsequen t hemi -
hypophysectomy [35]. In the other 29 patients (62%) of
their cohort, additional treatments such as adrenalectomy
or radiotherapy were required. However, the authors re-
ported no specific morbidity or rates of associated hypo-
pituitarism [35]. Instead, in patients with two-thirds pitu-
itary gland resection, favorable long-term remission rates
were reported in 18 (82%) of the 22 patients and new
endocrine deficits requiring hormone replacement in 9%
[19]. While we likewise noted low rates of pituitary in-
sufficiency, we could not attain remission rates as high as
those reported by Carr et al. when we limited the resection
to the lateral one-third of the pituitary gland [35]. This is
of interest given that the rate of histologically confirmed
adenomas reported by Carr and colleagues was lower than
we noted in our series (27% vs. 38% in our cohort) [19].
This finding might underscore the hypothesis that unsuc-
cessful histological adenoma confirmation does not seem
to be the only predictor of a low remission rate. In fact,
failure of histologic confirmation of an ACTH source is
an intriguing finding, as remission rates are reported even
in the absence of histological adenoma confirmation [67].
Nevertheless, most findings report on a lower initial re-
mission rate and a higher long-term recurrence rate in
patients without histological evidence of an adenoma
[51]. On the other hand, the higher remission rates report-
ed by Carr et al. might be due to removal of more pitui-
tary tissue, thus increasing the likelihood of removing
parts of the adenoma [39]. It is thus conceivable that re-
moving adenohypophyseal corticotroph tissue in the cen-
tral region of the gland known as the mucoid wedge might
increase the chance for long-term cure [39]. Comtois and
colleagues reported on 11 patients with absent intraoper-
ative adenoma visualization, in whom a partial hypophy-
sectomy of the central mucoid wedge was performed.
This resulted in some remission but significantly lower
cure rates as compared to those patients with intraopera-
tive adenoma identification [25]. However, Carr and col-
leagues also reported that unlike Comtois’ observation
[ 25 ] , i n t h e i r ex t en s i v e expe r i e n c e w i t h CD
microadenomas, tumors were more commonly located in
the lateral gland [19]. This underlines the finding that
ACTH adenomas were localized in the lateral aspect of
the pituitary gland in the majority of cases [37]. Likewise,
bilateral IPS sampling in Cushing patients confirms a lat-
eralization in the majority of cases [19, 37]. In the rare
event of negative intraoperative adenoma visualization,
the possibility of ectopic ACTH secretion has yet to be
considered, despite high sensitivity and specificity attrib-
uted to bilateral IPSS [7, 10]. There have been several
attempts to improve the predictive value of the intersinus
ACTH gradient. In 2012, Mulligan and colleagues dem-
onstrated improved adenoma lateralization using a
prolactin-adjusted intersinus ACTH gradient of > 1.4 in
their series [44]. Namely, IPSS prolactin can help to con-
firm correct catheter placement during venous sampling,
thus improving differentiation between CD and EAS in
the absence of proper IPS venous efflux [26, 50, 53].
However, further evaluation of the prolactin-adjusted
ACTH ratio is needed to prove reliable surgical guidance
[50]. Also, it has been suggested that anatomical variation
like intersinus communication might explain sampling
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failures [53]. In our previous work, we noted that IPS
asymmetry did not diminish the prediction of the adeno-
ma side [8]. However, the small sample size of this cohort
precludes us from undertaking statistical analysis to com-
pare outcome with regard to outflow symmetry. In addi-
tion, we have to keep in mind that surgeon experience is
of particular importance to guarantee a favorable outcome
in the treatment of CD [17, 36].
Given that CD is most commonly caused by a
microadenoma, tissue for pathologic diagnosis using standard
techniques might be very limited during surgical exploration
[29].While we sent suspicious tissue for frozen sectioning and
proceeded with lateral one third hypophysectomy in the case
of a negative result, it must be taken into consideration that the
reliability of frozen results varies considerably. It has been
shown that the addition of intraoperative cytological analyses
during surgery provides a useful armamentarium in the diag-
nosis of CD [52]. In fact, in some cases, the presence of an
adenoma can only be proven by cytological preparation,
which improves the adenoma identification rate and surgical
outcome compared to classical immunostainingmethods [38].
Given the similar remission rates attained when limiting the
approach to the lateral two-thirds compared to hemi-
hypophysectomy or subtotal hypophysectomy, subtotal resec-
tion might be preferred with regard to postoperative pituitary
hormone insufficiency, although results remain ambiguous
[17, 19]. As for ACTH-producing adenomas, the risk of post-
operative pituitary dysfunction can be higher than for other
types of pituitary adenomas, given the need for more exten-
sive intraoperative dissection of the pituitary gland, even in
the case of small adenomas [56]. Subtotal hypophysectomy
results in new hypopituitarism, with incidence rates ranging
from 1 to 35% [23, 33, 35]. Interestingly, Rees and colleagues
noted that the extent of surgical exploration predicted the de-
velopment of hypopituitarism (88% total hypophysectomy,
33% hemi-hypophysectomy, 14% selective adenomectomy),
but not remission (75% total hypophysectomy, 87% hemi-
hypophysectomy, 71% selective adenomectomy) in CD pa-
tients [55]. More surprisingly, Yamada et al. reported that
none of their 10 patients with hemi-hypophysectomy was not-
ed to have hypopituitarism requiring hormonal replacement
[66]. While hormonal insufficiencies vary considerably
among studies and are inconsistently reported, it is con-
ceivable that a limited resection results in lower inci-
dences of hormonal disorders following surgery. Thus,
our long-term cure rates in 31% of patients without the
need for additional therapies might still be acceptable
for the individual patient with regard to the low inci-
dence of new hormonal disorders. However, with a
follow-up in excess of 10 years, we noted that high
remission rates could be attained when interdisciplinary
multimodal therapies were combined with an initial sur-
gical approach. How to treat individual patients after
unsuccessful remission should be discussed by neuroen-
docrinologists and pituitary surgeons in order to develop
a proper strategy. We noted the use of metyrapone ther-
apy in up to 25% of patients for the long-term control
of hypercortisolism, an effective approach confirmed by
a recent meta-analysis [15]. Alternatively, repeat surgery
can be a safe next step prior to radiation or medical
therapy in CD patients [18, 59].
These options are mainly indicated in patients with
MR-proven sellar lesions, however. In addition, bilateral
adrenalectomy―which was required in no less than 33%
of patients in our cohort―has been described as an im-
portant option in CD, especially when other treatment
options have failed over time [21, 43]. Still, whether neg-
ative histology should trigger a different approach with
regard to multimodal treatment remains unclear.
To sum up, limiting pituitary gland resection to the lateral
one-third is a safe approachwith favorable outcome in the face
of new endocrine deficits, but remission rates are low.
Study limitations
The number of patients in our study is relatively small,
and statistical uncertainty owing to this small sample
size precluded us from undertaking statistical analysis
to compare outcome within the subgroups (i.e., adeno-
ma, ACTH hyperplasia, or positive Crooke-hyaline), or
with regard to outflow symmetry encountered during
IPS. However, it offers reliable insight derived from
long-term data obtained over two decades with a
follow-up of 14 years.
In contrast to microscopic TSS, an endoscopic approach
might be associated with higher gross total tumor removal
[40], but results remain ambiguous [2]. In the treatment of
CD, there seem to be no clear advantages of a purely endo-
scopic approach in terms of clinical outcome [1, 16, 45]. In
particular, endoscopic surgery for patients with CD has been
shown to have comparable results for microadenomas, with
presumably better results for macroadenomas [14], which
were not represented in the cohort presented here.
Given the long-term follow-up with recruitment of pa-
tients starting as early as 1997, patients were screened
with a 1.5 Tesla MRI for the depiction of a microadenoma
[6]. While some authors support the use of contrast-
enhanced 3 Tesla MRI for CD, most of these studies
comparing the detection rate of the pituitary 3 Tesla and
1.5 Tesla MRI are using different imaging protocols, thus
limiting the diagnostic accuracy of high-field-strength
MRI in patients with CD [65]. In particular, a higher
magnetic field might not be advantageous in the diagnosis
of microadenomas per se [32, 65].
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Conclusions
In CD patients with failed intraoperative adenoma visualiza-
tion, lateral one-third gland resection resulted in low morbid-
ity and long-term remission in 31% of patients without the
need for additional therapies. Bearing in mind the sample size
of this audit, the indication for lateral one-third-gland resec-
tion has to be critically appraised and discussed with the pa-
tients before surgery.
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